Want to see HK:2297 full AI Analyst Report?
2297 Stock Chart & Stats
HK$0.26
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.26
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$0.53
Previous CloseN/A
Volume40.00K
Average Volume (3M)3.71M
Market Cap
HK$320.91M
Enterprise ValueHK$318.45M
Total Cash (Recent Filing)HK$153.35M
Total Debt (Recent Filing)HK$24.83M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,401,358,800
10 Day Avg. Volume1,490,900
30 Day Avg. Volume3,709,666
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseA conservative capital structure with very low debt-to-equity (~0.04–0.07) and a sizable equity base provides balance-sheet flexibility to fund operations or withstand losses without immediate refinancing. This reduces near-term solvency risk and preserves strategic optionality over the next several months.
Improving Cash Burn In 2025Material improvement in free cash flow in 2025 versus 2024 indicates the company is narrowing its cash burn. While still negative, a trend toward lower outflows suggests operations and spending are stabilizing, easing near-term funding pressure and extending runway over a 2–6 month horizon.
Losses Smaller Than 2021–2022 PeakAlthough net losses remain sizable, they are materially smaller than the extreme 2021–2022 levels. This improvement implies cost reduction or operational scaling back has reduced cash drain, creating a firmer base from which to pursue margin recovery if revenues stabilize.
Bears Say
Sharp Revenue ContractionSubstantial top-line declines across consecutive years point to weakening demand or market share loss. Shrinking revenue undermines the ability to attain scale, pressures unit economics, and makes margin recovery and profitable growth materially more difficult over the medium term.
Negative Gross MarginA negative gross margin signals that core product economics are loss-making before overhead. This structural issue must be addressed via pricing, cost cuts, or product changes to enable sustainable operating profits; otherwise profitability recovery is unlikely.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow over multiple years shows the company is not self-funding and will likely rely on external financing. Persistent cash burn limits reinvestment, raises refinancing risk, and increases vulnerability to tighter capital conditions in the coming months.
Rainmed Medical Limited News
2297 FAQ
What was Rainmed Medical Limited’s price range in the past 12 months?
Rainmed Medical Limited lowest stock price was HK$0.19 and its highest was HK$0.53 in the past 12 months.
What is Rainmed Medical Limited’s market cap?
Rainmed Medical Limited’s market cap is HK$320.91M.
When is Rainmed Medical Limited’s upcoming earnings report date?
Rainmed Medical Limited’s upcoming earnings report date is Aug 27, 2026 which is in 41 days.
How were Rainmed Medical Limited’s earnings last quarter?
Rainmed Medical Limited released its earnings results on Mar 31, 2026. The company reported -HK$0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.035.
Is Rainmed Medical Limited overvalued?
According to Wall Street analysts Rainmed Medical Limited’s price is currently Overvalued.
Does Rainmed Medical Limited pay dividends?
Rainmed Medical Limited does not currently pay dividends.
What is Rainmed Medical Limited’s EPS estimate?
Rainmed Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rainmed Medical Limited have?
Rainmed Medical Limited has 1,401,358,800 shares outstanding.
What happened to Rainmed Medical Limited’s price movement after its last earnings report?
Rainmed Medical Limited reported an EPS of -HK$0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Rainmed Medical Limited?
Currently, no hedge funds are holding shares in HK:2297
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rainmed Medical Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.12%
12-Months-Change
Fundamentals
Return on Equity
-20.20%
Trailing 12-Months
Asset Growth
23.29%
Trailing 12-Months
Company Description
Rainmed Medical Limited
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
Technical Analysis
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Broncus Holding Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―